Business & Industry
Aligning Scientific Innovation with Commercial Reality in Drug Development
The "Valley of Death" in pharma is no longer just about scientific failure; it is about commercial irrelevance. This article examines the critical need to align R&D ambition with market reality early in development. It explores the evolution of the Target Product Profile (TPP) into the Target Value Profile (TVP), the role of the "commercial scientist," and strategies for integrated evidence generation that satisfy both regulators and payers.
Business & Industry
How Advanced Analytics is Redefining Pharma Project Prioritization
The era of "gut feeling" in pharmaceutical portfolio management is ending. This article explores how advanced analytics, machine learning, and predictive modeling are revolutionizing project prioritization. It details the shift to Monte Carlo simulations, integrated data lakes, and AI-driven decision support, enabling companies to objectively rank programs and optimize R&D return on investment.
Business & Industry
Rethinking Pipeline Value Beyond Peak Sales Forecasts
The traditional reliance on risk-adjusted Net Present Value (rNPV) and peak sales forecasts is failing to capture the true potential of modern pharmaceutical assets, particularly platform technologies. This article introduces holistic valuation frameworks like Real Options Analysis (ROA) and the Platform VISTA model, arguing for a shift toward valuing "strategic fit," "lifecycle potential," and the intangible equity of innovation engines.
Business & Industry
Building Resilient Pharma Portfolios in an Era of Scientific and Market Uncertainty
Pharmaceutical companies are radically redesigning portfolio strategies to survive a "triple threat" environment of scientific complexity, regulatory upheaval like the IRA, and capital scarcity. This analysis explores the shift from efficiency-driven models to resilience-first frameworks, detailing how leaders are embedding optionality into pipelines, embracing modality agnosticism, and using dynamic resource allocation to thrive amidst volatility.
BioPharma
Enhancing Lab Efficiency Through Cloud-Based Quality Systems
The manual control of laboratory quality may be a very difficult task to do, especially when considering the complexity of laboratory activities. Automating processes, providing visibility and traceability, assisting with risk management and change control, ensuring compliance, and providing...
Business & Industry
Algeria Showcases its Strength in African Pharma Sector
Abdelmadjid Tebboune, the Algerian president, went on to address participants at the African Ministerial Conference on Local Pharmaceutical Production and Health Technologies on November 27, 2025, with his message being read by Sifi Ghrieb, the prime minister.
The event, which...
BioPharma
The Rise of Pharma 4.0: Digital Twins, AI and Predictive Manufacturing
The pharmaceutical manufacturing industry stands at a transformative inflection point. For decades, manufacturing processes operated based on established protocols perfected through empirical experience and regulatory validation. While effective, these traditional approaches rely heavily on retrospective quality assurance, periodic environmental...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















